Zaptuzumab

Zaptuzumab (AD5-10) is a humanized monoclonal antibody targeting death receptor 5 (DR5) with high selective binding affinity. It specifically induces cancer cell death through caspase-mediated apoptosis and autophagic cell death (ACD) . Zaptuzumab can activate antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) . Additionally, it induces reactive oxygen species (ROS) production and reduces glutathione (GSH) levels. In various xenograft mouse tumor models, Zaptuzumab has demonstrated significant tumor growth inhibition and favorable safety profiles.